AR049203A1 - Nucleosidos de 3-b-d-ribofuranosiltiazolo(4,5-d)pirimidina y sus usos - Google Patents
Nucleosidos de 3-b-d-ribofuranosiltiazolo(4,5-d)pirimidina y sus usosInfo
- Publication number
- AR049203A1 AR049203A1 ARP050102308A ARP050102308A AR049203A1 AR 049203 A1 AR049203 A1 AR 049203A1 AR P050102308 A ARP050102308 A AR P050102308A AR P050102308 A ARP050102308 A AR P050102308A AR 049203 A1 AR049203 A1 AR 049203A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- cr7r8
- nhc
- alkynyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 24
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000005587 carbonate group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente se refiere a composicion farmacéutica que los contienen y usos. Reivindicacion 1: Un compuesto representado por la formula (1), R1a, R1b, y R1c son, de modo independiente, H, -C(O)R3, un grupo aminoácido racémico, L o D -C(O)CH2NHR4, - C(O)CH(alquil C1-6)NHR4, o R1b y R1c son, de modo colectivo, -C(O)-, que junto con los átomos de oxígeno forma un anillo carbonato de cinco miembros; R2 es H u OR5; R3 es un alquilo C1-18; R4 es H, -C(O)CH(alquil C1-6)NH2 o -C(O)CH(CH2-aril)NH2; R5 es, de modo independiente, H, alquilo C1-6, alquenilo C3-7, alquinilo C3-7, -(CR7R8)t(arilo C6-10), -(CR7R8)t(cicloalquilo C3-10); -(CR7R8)t(heterocíclico C4-10), -(CR7R8)t>1OH, -(CR7R8)t>0CO2-alquiloC1-18 -(CR7R8)t>0N(R9)CO2alquiloC1-18, y SO2(arilo), en donde t es un numero entero de 0 a 6 salvo indicacion en contrario, y en donde los restos alquilo, alquenilo, alquinilo, arilo, cicloalquilo y heterocíclico de los grupos anteriores están sustituidos con sustituyentes seleccionados, de modo independiente, de halo, ciano, nitro, trifluorometilo, trifluorometoxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxi, alcoxi C1-6, -NH2, -NH-alquilo, -N(alquilo)2, -NH-arilo, -N(alquil)(arilo), -N(arilo)2, -NHCHO, -NHC(O)alquilo, - NHC(O)arilo, -N(alquil)C(O)H, -N(alquil)C(O)alquilo, -N(aril)C(O)H, -N(aril)C(O)alquilo, -NHCO2alquilo, -N(alquil)CO2alquilo, -NHC(O)NH2, -N(alquilo)C(O)NH2, -NHC(O)NH-alquilo, -NHC(O)N(alquilo)2, -N(alquil)C(O)NH-alquilo, N(alquil)C(O)N(alquilo)2, - NHSO2-alquilo, -N(alquil)SO2-alquilo, -C(O)alquilo, -C(O)arilo, -OC(O)alquilo, -OC(O)arilo, -CO2-alquilo, -CO2-arilo, -CO2H, -C(O)NH2, -C(O)NH-alquilo, -C(O)N(alquilo)2, -C(O)NH-arilo, -C(O)N(arilo)2, -C(O)N(alquil)(arilo), -S(O)alquilo, - S(O)arilo, -SO2alquilo, - SO2arilo, -SO2NH2, -SO2-NH-alquilo y -SON(alquilo)2; R7 y R8 son, de modo independiente, H, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; y R9 es H, alquilo C1-6 o -CH2-arilo; con la condicion de que R5 no sea -CH3, y también con la condicion de que al menos uno de R1a, R1b, y R1c no sea H cuando R2 es H; o una de sus sales o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/018011 WO2005121162A1 (en) | 2004-06-07 | 2004-06-07 | 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049203A1 true AR049203A1 (es) | 2006-07-05 |
Family
ID=34959084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102308A AR049203A1 (es) | 2004-06-07 | 2005-06-07 | Nucleosidos de 3-b-d-ribofuranosiltiazolo(4,5-d)pirimidina y sus usos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20080070852A1 (es) |
| EP (1) | EP1758916B1 (es) |
| JP (1) | JP4856638B2 (es) |
| CN (1) | CN1964985A (es) |
| AR (1) | AR049203A1 (es) |
| AU (1) | AU2004320625B2 (es) |
| BR (1) | BRPI0418887A (es) |
| CA (1) | CA2566541C (es) |
| ES (1) | ES2399891T3 (es) |
| IL (1) | IL179529A0 (es) |
| IS (1) | IS8575A (es) |
| MX (1) | MXPA06014182A (es) |
| NO (1) | NO20070061L (es) |
| PA (1) | PA8635901A1 (es) |
| PE (1) | PE20060455A1 (es) |
| RU (1) | RU2006146204A (es) |
| SV (1) | SV2006002135A (es) |
| TN (1) | TNSN06403A1 (es) |
| TW (1) | TW200612969A (es) |
| UY (1) | UY28943A1 (es) |
| WO (1) | WO2005121162A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009486D0 (en) * | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
| PT2561872E (pt) * | 2004-12-17 | 2014-12-18 | Anadys Pharmaceuticals Inc | Compostos 3h-oxazolo[4,5-d]pirimidin-2-ona 3,5-di- -substituídos e 3,5,7-tri-substituídos e seus pró-fármacos |
| WO2007133865A2 (en) | 2006-04-11 | 2007-11-22 | Novartis Ag | Hcv/hiv inhibitors an their uses |
| GB0609178D0 (en) * | 2006-05-09 | 2006-06-21 | Univ Cardiff | Novel compounds |
| CL2007001427A1 (es) * | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
| BRPI0717741A2 (pt) * | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
| ES2530763T3 (es) * | 2007-06-25 | 2015-03-05 | Anadys Pharmaceuticals Inc | Procedimiento continuo de hidrólisis enzimática |
| EP2019113A1 (en) * | 2007-07-26 | 2009-01-28 | Anadys Pharmaceuticals, Inc. | New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| CN102596979B (zh) * | 2009-09-21 | 2014-12-10 | 吉里德科学公司 | 用于制备1’-取代碳核苷类似物的方法和中间体 |
| JP5909495B2 (ja) | 2010-10-08 | 2016-04-26 | ノバルティス アーゲー | スルファミドｎｓ３阻害剤のビタミンｅ製剤 |
| CN102153548B (zh) * | 2011-02-24 | 2012-11-28 | 河北大学 | 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用 |
| WO2022265964A1 (en) | 2021-06-14 | 2022-12-22 | VenatoRx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
| WO2023196458A1 (en) * | 2022-04-06 | 2023-10-12 | VenatoRx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
| CN116589606B (zh) * | 2022-12-01 | 2024-05-28 | 中国药科大学 | 一种丁酰化酵母葡聚糖及其制备方法、应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
| AU2002365412B2 (en) * | 2001-11-27 | 2008-10-09 | Anadys Pharmaceuticals, Inc. | 3-Beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof |
-
2004
- 2004-06-07 BR BRPI0418887-0A patent/BRPI0418887A/pt not_active IP Right Cessation
- 2004-06-07 CA CA2566541A patent/CA2566541C/en not_active Expired - Fee Related
- 2004-06-07 ES ES04785930T patent/ES2399891T3/es not_active Expired - Lifetime
- 2004-06-07 AU AU2004320625A patent/AU2004320625B2/en not_active Ceased
- 2004-06-07 RU RU2006146204/04A patent/RU2006146204A/ru not_active Application Discontinuation
- 2004-06-07 US US11/570,209 patent/US20080070852A1/en not_active Abandoned
- 2004-06-07 MX MXPA06014182A patent/MXPA06014182A/es not_active Application Discontinuation
- 2004-06-07 JP JP2007527161A patent/JP4856638B2/ja not_active Expired - Fee Related
- 2004-06-07 WO PCT/US2004/018011 patent/WO2005121162A1/en not_active Ceased
- 2004-06-07 CN CNA2004800432620A patent/CN1964985A/zh active Pending
- 2004-06-07 EP EP04785930A patent/EP1758916B1/en not_active Expired - Lifetime
-
2005
- 2005-06-06 UY UY28943A patent/UY28943A1/es not_active Application Discontinuation
- 2005-06-06 SV SV2005002135A patent/SV2006002135A/es unknown
- 2005-06-06 TW TW094118512A patent/TW200612969A/zh unknown
- 2005-06-07 PE PE2005000655A patent/PE20060455A1/es not_active Application Discontinuation
- 2005-06-07 PA PA20058635901A patent/PA8635901A1/es unknown
- 2005-06-07 AR ARP050102308A patent/AR049203A1/es not_active Application Discontinuation
-
2006
- 2006-11-23 IL IL179529A patent/IL179529A0/en unknown
- 2006-12-05 IS IS8575A patent/IS8575A/is unknown
- 2006-12-06 TN TNP2006000403A patent/TNSN06403A1/en unknown
-
2007
- 2007-01-04 NO NO20070061A patent/NO20070061L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1758916B1 (en) | 2012-11-21 |
| PA8635901A1 (es) | 2006-07-03 |
| AU2004320625A1 (en) | 2005-12-22 |
| SV2006002135A (es) | 2006-05-08 |
| JP2008501792A (ja) | 2008-01-24 |
| TW200612969A (en) | 2006-05-01 |
| MXPA06014182A (es) | 2007-06-25 |
| JP4856638B2 (ja) | 2012-01-18 |
| RU2006146204A (ru) | 2008-07-20 |
| CN1964985A (zh) | 2007-05-16 |
| WO2005121162A1 (en) | 2005-12-22 |
| TNSN06403A1 (en) | 2008-02-22 |
| EP1758916A1 (en) | 2007-03-07 |
| IL179529A0 (en) | 2007-05-15 |
| IS8575A (is) | 2006-12-05 |
| NO20070061L (no) | 2007-03-05 |
| ES2399891T3 (es) | 2013-04-04 |
| AU2004320625B2 (en) | 2009-08-27 |
| CA2566541A1 (en) | 2005-12-22 |
| US20080070852A1 (en) | 2008-03-20 |
| BRPI0418887A (pt) | 2007-10-30 |
| PE20060455A1 (es) | 2006-06-19 |
| UY28943A1 (es) | 2006-01-31 |
| CA2566541C (en) | 2012-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049203A1 (es) | Nucleosidos de 3-b-d-ribofuranosiltiazolo(4,5-d)pirimidina y sus usos | |
| AR019263A1 (es) | Compuestos derivados de hidroxamida del acido (4-arilsulfonilamino) tetrahidropiran-4-carboxilico, composiciones farmaceuticas y metodos de tratamiento. | |
| AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
| AR059687A1 (es) | Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion. | |
| TR200000447T2 (tr) | 5-Alkil-2-arilaminofenilasetik asitler ve türevleri. | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| AR056185A1 (es) | Derivados de (hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo, composicion farmaceutica y proceso de preparacion del compuesto | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| CO4700453A1 (es) | N-(INDOL-2-CARBONIL)-beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO AGENTES ANTIDIABETICOS | |
| ES2185338T3 (es) | Derivados de fumagilol y procedimientos para su fabricacion. | |
| WO2003062259A3 (en) | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents | |
| AR027744A1 (es) | Compuestos de eter difenilico utiles en terapia | |
| AR044342A1 (es) | Derivados de bencimidazol | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO5690579A2 (es) | Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos | |
| AR082453A1 (es) | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos | |
| ES2485867T3 (es) | Compuestos opioides de carboxamido | |
| CO5550437A2 (es) | Compuestos quimicos | |
| AR042404A2 (es) | Compuestos derivados de anilina | |
| CO5700781A2 (es) | Agonistas morfolinicos de la dopamina | |
| DE50304891D1 (de) | N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel | |
| AR016501A1 (es) | Compuestos inhibidores de las fkbp, composiciones farmaceuticas, uso para la preparacion de medicamentos y procesos de preparacion e intermediarios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |